液体活检生物标志物及其联合影像学在肺癌早期诊断中应用的研究进展  

Research progress on liquid biopsy and its combination of radiology in diagnosis of pulmonary nodules

作　　者：孙硕 王锋[1,2] 何立 杨文文 韩彪[1,2] 赵蒙蒙 陈昶 马敏杰[1,2] SUN Shuo;WANG Feng;HE Li;YANG Wenwen;HAN Biao;ZHAO Mengmeng;CHEN Chang;MA Minjie(The First Clinical Medical College of Lanzhou University,Lanzhou,730000,P.R.China;Department of Throcic Surgery,The First Hospital of Lanzhou University,Lanzhou,730000,P.R.China;Department of Thoracic Surgery,Shanghai Pulmonary Hospital,Tongji University School of Medicine,Shanghai,200433,P.R.China)

机构地区：[1]兰州大学第一临床医学院,兰州730000 [2]兰州大学第一医院胸外科,兰州730000 [3]同济大学附属上海市肺科医院胸外科,上海200433

出　　处：《中国胸心血管外科临床杂志》2023年第2期313-319,共7页Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

基　　金：甘肃省自然科学基金(21JR1RA118);胸外科关键技术与应用甘肃省国际合作基地专项基金。

摘　　要：肺癌是全世界死亡率最高的恶性肿瘤,其早期诊断评估对患者综合治疗有至关重要的作用。肺癌的术前早期诊断依赖于多种影像及肿瘤标志物指标,但因其假阳性率高而无法精准评估。液体活检生物标志物可通过非侵入式方法对外周血中循环肿瘤细胞及DNA进行检测,正逐渐成为肿瘤精准医疗领域强有力的诊断工具。本文就液体活检类生物标志物及其联合临床影像学特征在肺癌早期诊断中的研究进展作一综述。Lung cancer is a malignant tumor with the highest mortality worldwide,and its early diagnosis and evaluation have a crucial impact on the comprehensive treatment of patients.Early preoperative diagnosis of lung cancer depends on a variety of imaging and tumor marker indicators,but it cannot be accurately assessed due to its high false positive rate.Liquid biopsy biomarkers can detect circulating tumor cells and DNA in peripheral blood by non-invasive methods and are gradually becoming a powerful diagnostic tool in the field of precision medicine for tumors.This article reviews the research progress of liquid biopsy biomarkers and their combination with clinical imaging features in the early diagnosis of lung cancer.

关 键 词：液体活检 循环肿瘤细胞 影像学 影像组学 肺结节 综述 

分 类 号：R734.2[医药卫生—肿瘤]